Biomedica features FGF23 ELISA – intact and C-terminal – assays
Meet us at the OSTEOLOGIE Conference taking place from 22-24 June 2023 in Salzburg, Austria! We will exhibit at booth # 36 introducing our novel biomarker ELISA assays to investigate bone and cancer induced bone diseases (e.g. Periostin, Semaphorin 4D, LRG, and others).
Our focus will also be on FGF23, an important regulator of renal phosphate handling, with our FGF23 intact and FGF23 C-terminal ELISA assays.
Drop by – we’d love to see you there!
Related products:
DKK-1 ELISA
OPG ELISA
free sRANKL ELISA
osteomiR – miRNA bone biomarker
FluoBolt Klotho FIA
Testing Services (ELISA, Luminex, miRNA)
Wir freuen uns, mit unserem Partner Immundiagnostik vom 8.-10.3.2018 bei der Osteologie in Dresden auszustellen und Sie bei Stand # 25 begrüßen zu dürfen.
Produkthighlights:
NT-proBNP ELISA – kardialer Biomarker zur Risikokontrolle bei NSAR Therapie
bioactive Sclerostin ELISA – Inhibitor des Wnt-Signalweges
FGF23 (C-terminal) ELISA auch für Serum – Regulator des Phosphatstoffwechsels
Für einen Termin mit Biomedica’s Team für wissenschaftliche Produktspezialisten – Dr. Gabriela Berg und Dr. Annegret Bitzer – kontaktieren Sie uns bitte per e-mail.
Weitere Informationen zu Biomedica’s Biomarker Assays:
Bone Metabolism
Cardiovascular
Nephrology
Biomedica Analytical Testing Service
Link zu Immundiagnostik und zur Osteologie 2018.
Visit Biomedica at the FCVB at the Austria Center Vienna from April 20-22, booth #A3, to learn about Biomedica’s new biomarker ELISAs and to discuss your research projects:
Product Highlights:
proANP ELISA
NT-proBNP ELISA
NT-proCNP ELISA
(Big) Endothelin ELISA
FGF23 (C-terminal) ELISA
soluble Semaphorin 4 D ELISA
Additional information on Biomedica’s Biomarker Assays:
Bone Metabolism
Cardiovascular
Nephrology
Biomedica Analytical Testing Service
Useful links:
Scientific Programme FCVB 2018
ERA-EDTA 2018, May 24-27
Bella Center, Copenhagen, DK
ECTS 2018, May 26-29
VCC, Valencia, ES
Product Highlights:
bioactive Sclerostin ELISA
FGF23 (C-terminal) ELISA
Endostatin ELISA
soluble Semaphorin 4 D ELISA
total soluble Neuropilin-1 ELISA
Additional information on Biomedica’s Biomarker Assays:
Bone Metabolism
Cardiovascular
Nephrology
Biomedica Analytical Testing Service
Useful links:
ERA-EDTA 2018 Congress Website
Biomedica features bioactive Sclerostin ELISA and FGF23 ELISA
Biomedica is happy to exhibit at the ASBMR Annual Meeting in Montreal, Canada, from Sept 28 – Oct 1, booth # 708.
As a leading supplier of fully validated ELISA kits for clinical research of bone metabolism diseases Biomedica will present the new bioactive Sclerostin ELISA and some preliminary launch information on the mouse Periostin ELISA and intact FGF23 ELISA.
Visit our team at Biomedica’s booth # 708 to discuss your research and learn more about Biomedica and its product offers. Click on the products for detailed product information on:
bioactive Sclerostin ELISA
DKK-1 ELISA
OPG ELISA
free sRANKL ELISA
C-terminal FGF23 ELISA*
Periostin ELISA
soluble Semaphorin 4D ELISA
total soluble Neuropilin-1 ELISA
osteomiR – miRNA bone biomarker
*: not available in the USA
Meet us at the posters:
- Serum Circulating MicroRNAs as a Novel Biomarker for Osteoporotic Vertebral Fractures [SUN-0718]
- Validated and in-depth characterized sandwich ELISA for the quantification of mouse periostin [SUN-0865]
- Circulating miRNAs are associated with higher tibial cortical porosity in postmenopausal osteoporotic women with history of osteoporotic fractures [LB SUN-1148]
- Sandwich Immunoassay for the Specific Detection of Circulating Bioactive Sclerostin in comparison with other Sclerostin ELISA [MON-0724]
Meet Dr. Matthias Hackl from our partner TAmiRNA:
- Bone Turnover Marker Interest Group meeting [SUN 7:15pm, room 520 C]
Meet us at poster #P163 to learn about our C-terminal FGF23 ELISA and our nephrology product line!
From 27th-30th September, Biomedica will participate at the Annual Congress for German Nephrology taking place at the Estrel Convention Center in Berlin. The congress is hosted by the German Society for Nephrology (Deutsche Gesellschaft für Nephrologie, DGfN), which celebrates its 10th anniversary this year.
According to the DGfN, between four and six million Germans live with reduced kidney function. 80,000 of these patients are currently being treated with dialysis. Another 25,000 patients are under medical surveillance after a successful kidney transplant. Therapy for kidney diseases is cost-intensive; treatment for an average dialysis patient amounts to 40,000 Euros per year, amounting to 3 billion Euros health care costs annually. For more information go to http://www.die-nephrologen.de/fakten.html.
To ameliorate current treatment regimens and bring innovative technology to the clinic, the DGfN supports cooperation between ambulant and stationary clinicians and promotes the development of innovative and coordinated strategies to tackle the challenge of improving early diagnosis and long-term treatment of patients with kidney diseases.
One important aspect of improving outcomes is to stratify risk and detect diseases in an early stage. For this reason, Biomedica specialises in developing high-quality biomarker ELISAs for clinical research and application.
As our contribution to the scientific programme of the Kongress Für Nephrologie 2018, Biomedica will be presenting a poster about our C-terminal FGF-23 ELISA kit, a biomarker that has been linked to the clinical outcomes in both acute kidney injury and chronic kidney disease.
Dr. Annegret Bitzer, one of our Biomedica Product managers, is going to present the C-terminal FGF-23 poster (Poster #P163) on Friday 28th September from 2-3:30 pm, and will be happy to chat with you about the clinical significance of intact FGF-23 in kidney disease, as well as about the biomarkers in our innovative nephrology product line, which includes:
Human and mouse/rat Endostatin ELISAs
C-terminal FGF-23 ELISA
Bioactive Sclerostin ELISA
Osteoprotegerin ELISA
Total soluble Neuropilin-1 ELISA
Anti-C4d Antibodies
Coming soon:
Vanin-1 ELISA
intact FGF23 ELISA
We look forward to meeting you at the Congress!
Pricket TCR et al. show in their publication “C-Type Natriuretic Peptides in Coronary Disease” that “in contrast to the close association of NT-proBNP with cardiac function, and predictive value for outcome after myocardial infarction, plasma NT-proCNP (T-terminal C-type Natriuretic Peptide) is highly correlated with renal function and is an independent predictor of mortality and cardiac readmission in individuals with unstable angina.”
C-type Natriuretic Peptides in Coronary Disease
C-Type Natriuretic Peptides in Coronary Disease
Prickett TCR et al., Clin Chem, 2017; 63(1):316-324
Biomedica recently launched a novel validated NT-proCNP ELISA assay to support clinical research:
- EXTENSIVELY VALIDATED for clinical samples
- RELIABLE – 7 human serum based standards and 2 controls for biologically reliable data
- Excellent stability in all matrices after sample collection
- EASY – conventional 96-well format
For detailed information please click corresponding links:
BI-20812 NT-proCNP ELISA IFU
BI-20812 NT-proCNP ELISA Validation Data
BI-20812 NT-proCNP ELISA MSDS
Related publications
Sangaralingham SJ, McKie PM, Ichiki T, Scott CG, Heublein DM, Chen HH, Bailey KR, Redfield MM, Rodeheffer RJ, Burnett JC Jr. Hypertension. 2015. 65(6):1187-94. PMID: 25895587.
Abstract
C-type natriuretic peptide (CNP) is an endothelium-derived peptide that is released as a protective mechanism in response cardiovascular injury or disease. However, no studies have investigated circulating CNP, identifying clinical factors that may influence CNP and its relationship to cardiovascular disease in the general population. We studied 1841 randomly selected subjects from Olmsted County, MN (mean age, 63±11 years; 48% men). Plasma CNP was measured by a well-established radioimmunoassay and echocardiography, clinical characterization, and detailed medical record review were performed. We report that CNP circulates at various concentrations (median, 13 pg/mL), was unaffected by sex, was weakly associated by age, and that highest quartile of CNP identified a high-risk phenotype. Subjects with CNP in the highest quartile were associated with increased risk of myocardial infarction (multivariable-adjusted hazard ratio, 1.51; 95% confidence interval, 1.09-2.09; P=0.01) but not heart failure, cerebrovascular accidents, or death during a follow-up of 12 years. Addition of the highest quartile of CNP to clinical variables led to a modest increase in the integrated discrimination improvement for risk of myocardial infarction. In a large community-based cohort, elevated circulating CNP identified a high-risk phenotype that included cardiovascular comorbidities and left ventricular dysfunction, and provided evidence that highest concentrations of CNP potentially has prognostic value in predicting future risk of myocardial infarction. Together, these data from the general population highlight the potential value of CNP and support the need for additional studies to evaluate whether mechanisms regulating CNP could improve outcomes.
Semaphorin 4D is widely studied for its role in neural connectivity, vascularization, cell migration, the immune response, tumour progression, and bone remodeling.
Areas of interest: osteology, oncology, immunology, neurology
Semaphorin 4D ELISA for clinical samples
Biomedica offers a highly specific soluble Semaphorin 4D (sema4D) ELISA to support clinical research. The Semaphorin 4D ELISA is validated with real clinical samples for various sample matrices like serum or plasma and cell culture supernantants.
- GUARANTEED PERFORMANCE – rigorous validation and QC for plasma samples in clinical trials
- HIGHLY SPECIFIC – characterized antibodies and reagents
- REPRODUCIBLE – specific analysis of soluble non-shed SEMA4D
- RELIABLE – 7 human plasma based standards and 2 controls for biologically reliable data
- LOW SAMPLE VOLUME – only 10 µl / well required
- PROPRIETARY PRODUCT – in-house R&D and production
For detailed information please click corresponding links:
BI-20405 soluble Semaphorin product website
BI-20405 soluble Semaphorin 4D ELISA IFU
BI-20405 soluble Semaphorin 4D ELISA VAlidation Data
BI-20405 soluble Semaphorin 4D ELISA MSDS
Biomedica ELISA Service Quotation Form
Related literature
Semaphorin 4D as a guidance molecule in the immune system.
Kuklina E. Int Rev Immunol. 2021;40(4):268-273. doi: 10.1080/08830185.2021. PMID: 33787446.
Abstract
Semaphorin 4D (Sema4D) is a classic member of the semaphorin family involved in axonal guidance processes. The key effects of Sema4D in neurons are mediated by high affinity plexin receptors and are associated with cytoskeleton rearrangement, leading to growth cone collapse or regulation of cell migration. Along with this, the semaphorin is widely represented in the immune system and has a pronounced immunoregulatory activity. The involvement of Sema4D in the control of immune cell migration was shown almost twenty years ago, in one of the first studies of semaphorin. The emergence of such work was quite predictable, since the most well-known effects of Sema4D outside the immune system were associated precisely with the control of cell motility. However, after identification of CD72 as a specific Sema4D receptor in the immune system, studies of the immunoregulatory activity of semaphorin focused on its CD72-dependent effects unrelated to cytoskeleton rearrangement, and this trend continues up to now. Nevertheless, a number of recent studies demonstrating the presence of plexin receptors for Sema4D in the immune system forces us to return to the question of whether this semaphorin can play its classic role of a guidance molecule in relation to immune cells too. The review discusses Sema4D involvement in the control of immune cell migration, as well as the mechanisms of these effects and their potential contribution to the development and function of immune system.
Cost-utility analysis of fracture risk assessment using microRNAs compared to standard tools and no monitoring in the Austrian female population.
E.Walter, H. Dellago, J. Grillari, H.P. Dimai, M. Hackl, Bone, Volume 108, 2018, pages 44-54. Click link for full-text publication.
First comprehensive attempt to model the cost-effectiveness of circulating microRNAs for bone fracture risk assessment in comparison with DXA and FRAX®
The results demonstrate that the osteomiR™ kit can be a cost-effective alternative to established risk assessment strategies.
- osteomiR™ utilization can reduce fracture incidence in postmenopausal women
- osteomiR™ represents a cost-effective alternative to DXA, FRAX®
- Deterministic and probabilistic senstitivity analyses confirm robustness of the model
For detailed information please click corresponding links:
osteomiR™ microRNA biomarker product website
microRNA customized services FAQs
Biomedica microRNA Service Quotation Form
The only Sclerostin ELISA that utilizes specific EPITOPE MAPPED ANTIBODIES enabling the analysis of bioactive Sclerostin in clinical samples.
Bioactive Sclerostin ELISA (cat.no. BI-20472) Assay Highlights:
- HIGHLY SPECIFIC and DEFINED: capture antibody directed against Sclerostin’s bioactive site. Learn more
- RELIABLE: human serum based calibrators and controls, rigorously validated
- LOW SAMPLE VOLUME: 20 µl / well
- QUICK: total incubation time 3.5 h
First bioactive Sclerostin ELISA for clinical samples
Areas of interest: osteoporosis, cancer induced bone diseases, rheumatoid arthritis, chronic inflammation, kidney diseases, therapy monitoring of anabolic treatment.
For detailed information please click corresponding links:
BI-20472 bioactive Sclerostin product website
BI-20472 bioactive Sclerostin ELISA IFU
BI-20472 bioactive Sclerostin ELISA Validation Data
BI-20472 bioactive Sclerostin ELISA MSDS
RELATED PUBLICATIONS
Circulating bioactive sclerostin levels in an Austrian population-based cohort. Kerschan-Schindl K, Föger-Samwald U, Gleiss A, Kudlacek S, Wallwitz J, Pietschmann P. Wien Klin Wochenschr. 2022 Jan;134(1-2):39-44. doi: 10.1007/s00508-021-01815-0. Epub 2021 Feb 5. PMID: 33544208; PMCID: PMC8813720.
Abstract
Background: Circulating serum sclerostin levels are supposed to give a good estimation of the levels of this negative regulator of bone mass within bone. Most studies evaluating total serum sclerostin found different levels in males compared to females and in older compared to younger subjects. Besides an ELISA detecting total sclerostin an ELISA determining bioactive sclerostin has been developed. The aim of this study was to investigate serum levels of bioactive sclerostin in an Austrian population-based cohort.
Methods: We conducted a cross-sectional observational study in 235 healthy subjects. Using the bioactive ELISA assay (Biomedica) bioactive sclerostin levels were evaluated.
Results: Serum levels of bioactive sclerostin were higher in men than in women (24%). The levels correlated positively with age (r = 0.47). A positive correlation could also be detected with body mass index and bone mineral density.
Conclusion: Using the ELISA detecting bioactive sclerostin our results are consistent with data in the literature obtained by different sclerostin assays. The determination of sclerostin concentrations in peripheral blood thus appears to be a robust parameter of bone metabolism.
Two new publications using TAmiRNA’s osteomiR™ kit and microRNA services to investigate the role of microRNAs in osteoporosis:
Bone-related circulating microRNAs miR-29b-3p, miR-550a-3p and miR-324-3p and their association to bone microstructure and histomorphometry. X. Feichtinger, C. Muschitz, P. Heimel et al., Scientific Reports, Vol 8, Article Number : 4867 (2018). Click link for full-text publication.
Bone-related circulating miRNAs are signifcantly associcated to dynamic processes of bone, reflected by bone histomorpometry.
Altered microRNA Profile in Osteoporosis Caused by Impaired WNT Signaling. RE Mäkitie, M Hackl, R Niinimäki et al., J. Clin Endocrinol Metab. 2018 Mar 1 [Epub ahead of print]. Click link for abstract.
Circulating miRNA pattern reflecting WNT1 Mutation Status provide novel insights into the mode of Action of WNT1 osteoporosis.
For detailed information please click corresponding links:
osteomiR™ microRNA biomarker product website
osteomiR™ key publications osteomiR™ FAQs
microRNA customized services
microRNA customized services FAQs
Biomedica microRNA Service Quotation Form
Biomedica is happy to introduce our novel Neuropilin-1 ELISA that measures total human soluble NRP1 in biological samples utilizing specific EPITOPE MAPPED ANTIBODIES.
Assay Highlights:
- HIGHLY SPECIFIC and DEFINED – epitope mapped antibodies
- RELIABLE: human serum based calibrators and controls, rigorously validated
- LOW SAMPLE VOLUME: 10 µl / well
- QUICK: total incubation time 4 h
- PROTOCOLS available for urine, cc supernatants and non-human samples
Novel Neuropilin-1 ELISA
Areas of interest: neurological disorders, oncology, nephrology, osteology, cardiology
For detailed information please click corresponding links:
BI-20409 total soluble Neuropilin-1 product website
BI-20409 total soluble Neuropilin-1 ELISA IFU
BI-20409 total soluble Neuropilin-1 ELISA Validation Data
BI-20409 total soluble Neuropilin-1 ELISA MSDS
Biomedica ELISA Service Quotation Form
Related literature
Serum concentrations of neuropilin-1 in women with endometriosis. Barberic M, Pavicic Baldani D, Rogic D, Kralik S.Scand J Clin Lab Invest. 2020 Jul;80(4):271-276. doi: 10.1080/00365513.2020.1728785. Epub 2020 Feb 18. PMID: 32069143.
Abstract
Objective of this work is to investigate, for the first time, serum concentration of neuropilin-1 (NRP-1), aiming to evaluate its diagnostic performance in endometriosis and usability as a potential non-invasive serum marker of endometriosis. Two hundred women were treated laparoscopically. After laparoscopic surgery women were divided into two groups: 120 women diagnosed with endometriosis and 80 healthy women (control group). Blood samples were taken from all women undergoing laparoscopy half an hour before the induction of anesthesia, for the purpose of collection of serum. The level of NRP-1 in serum was assayed by a standardised sandwich enzyme-linked immunosorbent assay. Differences between endometriosis and healthy control group in NRP-1 levels were significant. All values were significantly and several times higher in patients group, p < .001. After receiver operating characteristic analysis, the area under curve was 0.97 (95% confidence interval: 0.941 to 0.989, p < .0001) at 11 µg/L cut-off level for NRP-1. Preliminary threshold values for NRP-1 in serum were assumed to serve as diagnostic parameters with sensitivity of 99.3% and specificity of 97.8%. Serum concentration of NRP-1 can be considered as a potentially good laboratory diagnostic, non-invasive marker for endometriosis.
Renal dysfunction may limit the clinical application of NT-proBNP in the diagnosis of heart failure.
Big ET is an excellent biomarker candidate for the diagnosis of HFpEF in CKD, independent of GFR
This was recently discussed in: Renal function, N-terminal Pro-B-Type natriuretic peptide, propeptide big-endothelin and patients with heart failure and preserved ejection fraction.
Ingrid Gergei, Bernhard K. Krämer, Hubert Scharnagl, Tatjana Stojakovic, Winfried März. Peptides. 2018 Apr 21. pii: S0196-9781(18)30071-8. Click link for abstract.
Highlights:
- NT-proBNP is strongly associated with GFR and shows an exponential negative correlation with GFR decline.
- Big ET-1 is much less affected by GFR decline than NT-proBNP
- A single cut-off point is sufficient in the diagnosis of HFpEF in CKD, independent of GFR
Big ET for the diagnosis of HFpEF
The Biomedica Big Endothelin ELISA Assay is:
- EASY – can be used in every lab
- ROBUST & fully VALIDATED
- CE registered – for IVD use in EU
- GOOD ANALYTE STABILITY in serum and plasma
Related publications
Prognostic value of plasma big endothelin-1 in left ventricular non-compaction cardiomyopathy.
Fan P, Zhang Y, Lu YT, Yang KQ, Lu PP, Zhang QY, Luo F, Lin YH, Zhou XL, Tian T. Heart. 2021. 107(10):836-841. PMID: 33055147; PMCID: PMC8077223.
Abstract
Objective: To determine the prognostic role of big endothelin-1 (ET-1) in left ventricular non-compaction cardiomyopathy (LVNC).
Methods: We prospectively enrolled patients whose LVNC was diagnosed by cardiac MRI and who had big ET-1 data available. Primary end point was a composite of all-cause mortality, heart transplantation, sustained ventricular tachycardia/fibrillation and implanted cardioverter defibrillator discharge. Secondary end point was cardiac death or heart transplantation.
Results: Altogether, 203 patients (median age 44 years; 70.9% male) were divided into high-level (≥0.42 pmol/L) and low-level (<0.42 pmol/L) big ET-1 groups according to the median value of plasma big ET-1 levels. Ln big ET-1 was positively associated with Ln N-terminal pro-brain natriuretic peptide, left ventricular diameter, but negatively related to age and Ln left ventricular ejection fraction. Median follow-up was 1.9 years (IQR 0.9-3.1 years). Kaplan-Meier analysis showed that, compared with patients with low levels of big ET-1, those with high levels were at greater risk for meeting both primary (p<0.001) and secondary (p<0.001) end points. The C-statistic estimation of Ln big ET-1 for predicting the primary outcome was 0.755 (95% CI 0.685 to 0.824, p<0.001). After adjusting for confounding factors, Ln big ET-1 was identified as an independent predictor of the composite primary outcome (HR 1.83, 95% CI 1.27 to 2.62, p=0.001) and secondary outcome (HR 1.93, 95% CI 1.32 to 2.83, p=0.001).
The big ET-1 concentrations were quantified using the Big Endothelin-1 ELISA Kit (NO. BI-20082H; Biomedica, Wien, Austria.
Related publications
Li P, Schmidt IM, Sabbisetti V, Tio MC, Opotowsky AR, Waikar SS. Clin J Am Soc Nephrol. 2020. 8;15(6):784-793. PMID: 32381583.
Abstract
Background and objectives: Endothelin-1 is a potent endothelium-derived vasoconstrictor peptide implicated in the pathogenesis of hypertension, congestive heart failure, and inflammation, all of which are critical pathophysiologic features of CKD.
Design, setting, participants, & measurements: To test the hypothesis that plasma endothelin-1 levels are associated with increased risks of mortality and hospitalization in patients with chronic kidney failure, we measured plasma endothelin-1 levels in a prospective cohort of 794 individuals receiving maintenance hemodialysis. The primary outcomes were time to death and time to hospitalization.
Results: The median plasma endothelin-1 level was 2.02 (interquartile range, 1.57-2.71) pg/ml. During a median follow-up period of 28 (interquartile range, 21-29) months, 253 individuals (32%) died and 643 individuals (81%) were hospitalized at least once. In multivariable models adjusted for demographic, clinical, and laboratory variables, individuals in the highest quartile of plasma endothelin-1 had a 2.44-fold higher risk of death (hazard ratio, 2.44; 95% confidence interval, 1.61 to 3.70) and a 1.54-fold higher risk of hospitalization (hazard ratio, 1.54; 95% confidence interval, 1.19 to 1.99) compared with individuals in the lowest quartile. The Harrell C-statistic of the fully adjusted model increased from 0.73 to 0.74 after addition of natural log-transformed plasma endothelin-1 (P<0.001) for all-cause mortality, and increased from 0.608 to 0.614 after addition of natural log-transformed plasma endothelin-1 (P=0.002) for hospitalization.
Conclusions: Higher plasma endothelin-1 is associated with adverse clinical events in patients receiving hemodialysis independent of previously described risk factors.
Podcast: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2020_05_15_CJN11130919.mp3.
Keywords: Chronic; Cohort Studies; Endothelin-1; Endothelins; Inflammation; Kidney Failure; Prospective Studies; Renal Insufficiency; Vasoconstrictor Agents; cardiovascular disease; dialysis; endothelium; heart failure; hemodialysis; hospitalization; hypertension; mortality; risk factors.
Biomedica is happy to introduce its new brochure featuring biomarker ELISAs for clinical research of cancer diseases.
Click link for BIOMEDICA ONCOLOGY PRODUCT LEAFLET.
Detailed product information:
DKK-1 ELISA, BI-20413
OPG ELISA, BI-20403
free sRANKL ELISA, BI-20462
Sclerostin ELISA, BI-20492
bioactive Sclerostin ELISA, BI-20472
FGF23 ELISA, BI-20702
Periostin ELISA, BI-20433
Semaphorin 4D ELISA, BI-20405
Endostatin ELISA, BI-20742
total sNRP1 ELISA, BI-20409
Biomedica ELISA Service Quotation Form
Biomedica features new biomarkers for cancer research at ISOBM 2018
Biomarkers have the potential to improve clinical results in cancer prevention, diagnosis and therapy. At the ISOBM Congress, relevant new findings in research, diagnosis and clinical oncology will be discussed with the goal to ultimately improve patient’s state and survival.
Visit Biomedica’s team at the posters and learn more about the recently released ELISA assays for total soluble Neuropilin-1 and soluble Semaphorin 4D for cancer research:
- Development of a Sandwich ELISA for Total Soluble Neuropilin-1 – A Decoy Receptor for VEGF
- Quantification of Pro-angiogenic, Soluble Human Semaphorin 4D by Sandwich ELISA
Click on the products for detailed product information on:
Biomedica’s NT-proBNP ELISA complies with strict quality standards confirmed by RfB, an accredited international provider for proficiency testing for NT-proBNP. The Biomedica NT-proBNP ELISA successfully passes QC circle.
NT-proBNP ELISA successfully passes QC circle
– Link to RfB NT-proBNP Biomedica Certificate Proficiency Testing
-Link to RfB NT-proBNP Comments and Evaluation
FEATURES & BENEFITS
Biomedica NT-proBNP ELISA, cat# SK-1204:
- EASY – can be used in every lab
- RELIABLE – proved by RfB proficiency testing
- ROBUST & fully VALIDATED
- CE registered – for IVD use in EU
- GOOD ANALYTE STABILITY in serum and plasma
RELATED PUBLICATIONS
NT-proBNP as a Cornerstone for Prognosis in Valve Disease: All We Need Is Blood. Bergler-Klein J. J Am Coll Cardiol. 2020 Apr 14;75(14):1673-1675. doi: 10.1016/j.jacc.2020.02.030. PMID: 32273032.
NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) and the Risk of Stroke. Di Castelnuovo A, Veronesi G, Costanzo S, Zeller T, Schnabel RB, de Curtis A, Salomaa V, Borchini R, Ferrario M, Giampaoli S, Kee F, Söderberg S, Niiranen T, Kuulasmaa K, de Gaetano G, Donati MB, Blankenberg S, Iacoviello L; BiomarCaRE Investigators. Stroke. 2019 Mar;50(3):610-617. doi: 10.1161/STROKEAHA.118.023218. PMID: 30786848.
Abstract
Background and Purpose- NT-proBNP (N-terminal pro-B-type natriuretic peptide) is a risk factor for atrial fibrillation and a marker of cardiac function used in the detection of heart failure. Given the link between cardiac dysfunction and stroke, NT-proBNP is a candidate marker of stroke risk. Our aim was to evaluate the association of NT-proBNP with stroke and to determine the predictive value beyond a panel of established risk factors. Methods- Based on the Biomarkers for Cardiovascular Risk Assessment in Europe-Consortium, we analyzed data of 58 173 participants (50% men; mean age 52 y) free of stroke from 6 community-based cohorts. NT-proBNP measurements were performed in the central Biomarkers for Cardiovascular Risk Assessment in Europe laboratory. The outcomes considered were total stroke and subtypes of stroke (ischemic/hemorrhagic). Results- During a median follow-up time of 7.9 years, we observed 1550 stroke events (1176 ischemic). Increasing quarters of the NT-proBNP distribution were associated with increasing risk of stroke ( P for trend <0.0001; multivariable Cox regression analysis adjusted for risk factors and cardiac diseases). Individuals in the highest NT-proBNP quarter (NT-proBNP >82.2 pg/mL) had 2-fold (95% CI, 75%-151%) greater risk of stroke than individuals in the lowest quarter (NT-proBNP <20.4 pg/mL). The association remained unchanged when adjusted for interim coronary events during follow-up, and though it was somewhat heterogeneous across cohorts, it was highly homogenous according to cardiovascular risk profile or subtypes of stroke. The addition of NT-proBNP to a reference model increased the C-index discrimination measure by 0.006 ( P=0.0005), yielded a categorical net reclassification improvement of 2.0% in events and 1.4% in nonevents and an integrated discrimination improvement of 0.007. Conclusions- In European individuals free of stroke, levels of NT-proBNP are positively associated with risk of ischemic and hemorrhagic stroke, independently from several other risk factors and conditions. The addition of NT-proBNP to variables of established risk scores improves prediction of stroke, with a medium effect size.